Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Receivables - Net: 2016-2024

Historic Receivables - Net for UroGen Pharma (URGN) over the last 6 years, with Dec 2024 value amounting to $20.3 million.

  • UroGen Pharma's Receivables - Net fell 13.59% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.7 million, marking a year-over-year decrease of 13.59%. This contributed to the annual value of $20.3 million for FY2024, which is 31.46% up from last year.
  • According to the latest figures from FY2024, UroGen Pharma's Receivables - Net is $20.3 million, which was up 31.46% from $15.4 million recorded in FY2023.
  • UroGen Pharma's Receivables - Net's 5-year high stood at $20.3 million during FY2024, with a 5-year trough of $7.0 million in FY2020.
  • Moreover, its 3-year median value for Receivables - Net was $15.4 million (2023), whereas its average is $16.1 million.
  • Data for UroGen Pharma's Receivables - Net shows a peak YoY spiked of 66.27% (in 2021) over the last 5 years.
  • UroGen Pharma's Receivables - Net (Yearly) stood at $7.0 million in 2020, then skyrocketed by 66.27% to $11.7 million in 2021, then grew by 8.42% to $12.7 million in 2022, then rose by 21.56% to $15.4 million in 2023, then surged by 31.46% to $20.3 million in 2024.